Abstract Radionecrosis is a potentially devastating complication of external beam radiotherapy (XRT). Intraventricular compartmental radioimmunotherapy (cRIT) using 131 I-3F8 or 131 I-8H9 can eradicate malignant cells in the CSF. The incidence of radionecrosis using cRIT 131 I based intraventricular radioimmunotherapy, when used alone or in combination with conventional craniospinal CSI-XRT is unknown. We retrospectively analyzed the incidence of radionecrosis in two cohorts of pediatric patients treated with both CSI-XRT and cRIT at MSKCC since 2003: patients with metastatic CNS neuroblastoma (NB) and medulloblastoma (MB). 94 patients received both CSI-XRT and cRIT, two received cRIT alone, median follow up 41.5 months (6.5-124.8 months). Mean CSI-XRT dose was 28 Gy (boost to the primary tumor site up to 54 Gy) in the MB cohort, and CSI XRT dose 18-21 Gy (boost to 30 Gy for focal parenchymal mass) in the NB cohort. For MB patients, 20 % had focal re-irradiation for a second or more subsequent relapse, mean repeat-XRT dose was 27.5 Gy; seven patients with NB had additional focal XRT. Median CSF cRIT dose was 18.6 Gy in the MB cohort and 32
Introduction
Radionecrosis is a potentially devastating long-term complication of external-beam radiotherapy (XRT) including craniospinal radiation therapy (CSI), with a reported incidence in some series as high as 5 %. [1, 2] Suspicious radiographic lesions are initially noted on consecutive MRIs taken at various intervals. The diagnosis of radionecrosis is ultimately based on a combination of clinical, radiological and dosimetric criteria, typically confirmed by histopathology. Intraventricular compartmental radioimmunotherapy (cRIT) using 131 I-3F8 or 131 I-8H9 monoclonal antibodies has been used to eradicate malignant cells in the cerebrospinal fluid (CSF) space, with Kim Kramer completed the statistical analysis.
& Kim Kramer kramerk@mskcc.org no long term neurologic toxicity [3, 4] . The incidence of radionecrosis among children with malignant brain and/or spinal (CNS) tumors treated with XRT, CSI, and cRIT is unknown.
Methods
We performed a retrospective single-center study analyzing the incidence and clinical course of radionecrosis in patients treated with CSI-XRT with focal parenchymal boost and cRIT at Memorial Sloan Kettering Cancer Center (MSK) since 2003. A waiver for collection of patient data was approved by the MSK IRB. Patients in this analysis had a histopathologically confirmed diagnosis of recurrent/ high risk-MB or NB metastatic to the brain parenchyma, spinal cord, or leptomeninges. Patients with MB received conventional CSI as part of upfront therapy at initial diagnosis (CSI-XRT 23.4 Gy for patients with standard-risk disease and 36 Gy for patients with high-risk disease.) All patients with MB received an initial boost to the primary tumor bed to 54 Gy. Patients with metastatic CNS NB were treated with CSI-XRT up to 21.6 Gy, with an additional boost up to 9 Gy to focal metastatic lesions as previously described [3] .
cRIT therapy
Patients were enrolled on an IRB-approved protocol testing cRIT with 131 I-3F8 (NCT00445965), or 131 I-8H9 (NCT00089245) for individuals with high-risk metastatic CNS tumors. For both trials, patients had to meet eligibility criteria: having a refractory or recurrent NB or MB with a predilection for leptomeningeal dissemination. Tumors were known to express GD2 for 3F8, or 8H9 reactivity by immunohistochemistry. Eligible patients had no rapidly deteriorating neurologic examination or obstructive hydrocephalus, an absolute neutrophil count [1000/ul, platelet count [50,000/ul, blood urea nitrogen \30 mg/dl, serum bilirubin \3.0 mg/dl, and serum creatinine \2 mg/ dl. For patients receiving cRIT with 131 I-3F8, XRT was given up to 72 Gy to focal brain parenchymal lesions and/ or up to 45 Gy CSI; for patients receiving 131 I-8H9 cRIT, there was no limit to prior XRT absorbed dose (in Gy). For all patients, there was at least a 3 week interval between XRT and cRIT. Ommaya catheter position, patency and CSF flow were evaluated in all patients pre-treatment using 111-Indium diethylene triamine pentaacetic acid (DTPA) scintigraphy studies. Patients had baseline MRI studies of the brain and spinal cord and CSF cytology examination approximately 1 month prior to and after cRIT.
Murine monoclonal antibody 3F8 targeting disialoganglioside GD2, and 8H9 targeting B7-H3 were purified and radiolabeled at MSKCC using the iodogen method as detailed in the respective investigational new drug applications, with specific activities averaging 5 mCi/mg 3F8 or 50 mCi/mg 8H9. Patients received an oral saturated solution of potassium iodide (SSKI) and liothyronine to suppress thyroid function and uptake of any free radioiodine and were premedicated with acetaminophen, lorazepam, and diphenhydramine.
cRIT injections were routinely administered in the outpatient setting. Intra-Ommaya treatments were performed as follows: For 3F8, a weekly injection of 131 I-3F8 (10 mCi) for a total of up to four injections. The maximum total administered activity was up to 40 mCi but with the total cRIT CSF absorbed dose not to exceed 24 Gy as projected based on pre-therapy dosimetry estimates with a 2 mCi I-3F8 test administration). The 10 mCi therapy administrations were based on the maximum tolerated activity established in a phase I study [4] . For 8H9: 1 or 2 monthly injections 131 I-8H9 (10-70 mCi/injection); dosing was based on a phase I dose-escalation level at the time of patient entry or on an expanded phase II cohort treated at 50 mCi 131 I-8H9 per injection. The administered activity was adjusted based on CSF volume for patients less than 3 years of age (B12 months, 50 % dose reduction; 13-36 months, 33 % dose reduction; [36 months, full dose). Clinical status, vital signs and neurologic examination were monitored overnight. Repeat therapy injections were administered in the absence of grade three or four toxicity using the National Cancer Institute Common Toxicity Criteria [5] .
Upon completion of the cRIT protocol, routine MR of the brain and spine was performed approximately 1 month after the last injection, and thereafter every 3 months. Patients followed longer than 5 years after the completion of treatment typically had routine brain MR surveillance on a annual basis.
Dosimetry
Pre-treatment cRIT dosimetry was performed based on the 2 mCi administration of the 131 I-or, more recently, the 124 I-MoAb and serial whole body SPECT or PET, respectively. Biodistribution and activity concentrations in the craniospinal axis and radiation doses to plaques of disease and surrounding normal tissues were determined as described [3] . The measured time-activity concentration data were corrected for physical decay of the 131 I or the 124 I to the time of administration and then fit to exponential functions as previously described. 4 Taking into account the physical half-life of 131 I (the radionuclide to be used in the subsequent therapies), the resulting functions were integrated to ''infinite'' time, that is, to complete decay, to yield the cumulated activity concentrations (i.e. total number of decays in lCi-h/mCi/gm) of 131 I in the respective source regions.
131 I-MoAb absorbed doses for target regions including CSF, ventricles, spinal cord, normal brain, and blood were calculated assuming complete local absorption of the 131 I beta radiation and ignoring the gamma radiation contribution.
Injections were followed by pharmacokinetic studies over 48 h. Measured aliquots of CSF and blood were counted in a scintillation well counter calibrated for 131 I to estimate the time-dependent activity concentrations. The respective time-activity concentration data were again fit to exponential functions and integrated to yield the source region cumulated activity concentrations and the various target-region absorbed doses calculated, as previously described [6] .
Results
Ninety-six patients (58 CNS NB; 38 MB) 94 received both CSI-XRT and cRIT, with median follow-up 41.5 months (range 6.5-124.8 months) ( Table 1) . Within the MB cohort, there were two additional patients younger than 3 years at diagnosis who were treated with chemotherapy and cRIT alone, and no conventional external beam radiation therapy; four patients were treated with M3 disease post CSI. For all other patients with recurrent MB, overall mean CSI absorbed dose was 28 Gy (additional boost to primary tumor mass 23.8 Gy, totaling 54-55.8 Gy); 20 % had re-irradiation at a later date with a mean repeat-XRT absorbed dose of 27.5 Gy. The median CSF absorbed dose by cRIT was 18.6 (10.4-131.4 Gy). The time between CSI and cRIT varied in this patient population in that the majority was treated with cRIT at the time of MB recurrence, with a mean time from initial diagnosis to cRIT 34.5 months.
For those with CNS NB recurrence, patients were treated uniformly with a combined approach incorporating CSI followed by cRIT 3 , with a mean time from completion of CSI to cRIT of approximately 4 weeks. The overall mean CSI absorbed dose was 21.7 Gy (with an additional boost to parenchymal tumor masses of 10.8 Gy); 7 had reirradiation at a later date with focal or stereotactic XRT, mean repeat-XRT absorbed dose of 24 Gy. The mean CSF absorbed dose by cRIT was 32.1 (4.3-147.3 Gy).
Radionecrosis
Only one patient underwent resection of a 0.6 cm hemorrhagic periventricular white matter lesion confirmed to be necrosis and granuation tissue, 2.5 years after XRT. The patient presented at age 23 months with high-risk metastatic NB and was treated with multiagent chemotherapy, two tandem autologous bone marrow transplants including totalbody radiation of 12 Gy, and focal RT to the primary site of 24.25 Gy. Approximately 1.5 years after initial diagnosis, the patient presented with two parenchymal CNS lesions causing symptomatic hydrocephalus. Treatment included surgical resection of the lesions, CSI 21.60 Gy and a whole brain boost of 3.6 Gy, followed by 131 I-8H9 cRIT (total adminstered activity: 64 mCi). A complete remission was achieved. Over 2.5 years later, a 0.6-cm hemorrhagic right parietal periventricular white matter lesion was noted on routine brain MRI, in the region of prior focal RT boost. Radiographically, the lesion was described as a 0.6 cm marginally enhancing lesion identified within the deep right parietal periventricular white matter, associated with a small amount of edema and containing intralesional hemorrhage supported by a blooming effect on the Bo portion of the diffusion weighted sequences. This lesion was thought to likely represents a brain metastasis, less likely to represent an occult vascular malformation or cavernous malformation given the rim like marginal enhancement. The patient was asymptomatic. The lesion was resected, with histopathology noting granulation tissue, necrosis, and hemosiderin; no tumor was seen. Although there is radiographic evidence of punctate cavernomas, no further evidence of radionecrosis has been noted on routine scans monitored over the ensuing six-plus years.
Discussion
Radionecrosis can be a devastating complication following CNS radiation. Although the exact incidence and clinical spectrum of radiation necrosis are variable, large series report an incidence of 4-5 % in children with CNS tumors [1, 7] . Symptomatic patients often require surgical resection, corticosteroids, and/or hyperbaric oxygen. More recently, treatment with bevacizumab has resulted in a significant radiographic response of radionecrosis [8] . We undertook the current analysis to determine if children treated with both XRT and cRIT have an increased risk of radionecrosis.
For the initial phase II 131 I-3F8 study where the risk of radionecrosis was unknown, a conservative treatment approach was followed such that patients with a history of [72 Gy focal CNS RT or 45 Gy CSI were excluded. Further, patients with a history of prior CSI, were restricted to receive a total of four therapy injections (maximum total administered activity: 40 mCi), specifically not to exceed a total CSF cRIT absorbed dose of 24 Gy based on pretherapy dosimetry analysis. Using these guidelines, even in a heterogeneous patient population, no patient had any evidence of radionecrosis. For the patients treated with 131 I-8H9, the number of cRIT therapy injections was not limited by prior XRT dose or by cRIT dosimetry. The only occurrence of radionecrosis was in a patient with NB with an extensive radiation therapy history: total-body radiation (1200 cGy) and focal primary tumor radiation (1225 cGy) to the left neck after initial diagnosis, and then CSI (2160 cGY) with whole brain boost (360 cGy) and cRIT (64 mCi 131 I-8H9) at the time of CNS relapse. The total administered activity to the brain in the area that developed necrosis was 37.20 Gy XRT, plus 64 mCi cRIT with 131 I-8H9. Even with this extensive XRT history, the lesion was found on a routine surveillance brain MR when the patient had no symptoms. The reported incidence of symptomatic and asymptomatic radionecrosis observed was 8.4 and 6.9 %, respectively, in other patients treated with stereotactic radiosurgery for brain metastases, often correlating with the location of the lesions (superficial, deep, or central) [9] . We observed no increased risk in the seven patients with NB who were treated with a subsequent focal or stereotactic boost. The antibody was conjugated with 131 I, with a physical half-life (8.04 days) to be commensurate with the biological half-life on the antibody in the CSF. The mean range of the b-particles emitted by 131 I is short (0.37 mm), therefore sparing the CNS tissue from 131 I decays within the CSF compartment. As a consequence tumor cells within the CSF compartment will get maximum dose, yet with rapid fall off in b dose with distance from the CSF (to almost zero within 2 mm). Even considering a conservative denominator for patients who have lived long enough for the full time-period risk for radionecrosis, i.e. 3 and 4 years, point estimate for radionecrosis in this cohort is approximately 2 %. The radiation dose to the CNS from the RIT is likely to be a small incremental addition above and beyond the external beam dose contribution. This study supports that notion that in pediatric patients with malignant CNS tumors, the opportunity for dose escalation with cRIT might be higher than previously appreciated.
Conclusion
The median follow-up in the current study was 41.5 months (6.5-124.8 months), within the expected time frame for a complication such as radionecrosis to be clinically demonstrable. The risk of radionecrosis in children treated with XRT and cRIT appears minimal (\1 %).
No neurologic deficits secondary to radionecrosis have been observed in long-term survivors treated with these combined modalities, including patients who underwent repeat-XRT. Administration of cRIT may safely proceed in patients with CSI-XRT without increasing the risk of radionecrosis. Patient-specific radiation dosimetry of cRIT (based on pre-treatment tracer studies) as well as XRT is likely important for achieving such a favorable result.
